329 related articles for article (PubMed ID: 29572645)
1. Effects of the Serotonin 5-HT
Newman-Tancredi A; Varney MA; McCreary AC
Neurochem Res; 2018 May; 43(5):1035-1046. PubMed ID: 29572645
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
3. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
4. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC; Varney MA; Newman-Tancredi A
Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
[TBL] [Abstract][Full Text] [Related]
5. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
6. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
[TBL] [Abstract][Full Text] [Related]
7. The selective 5-HT
Fisher R; Hikima A; Morris R; Jackson MJ; Rose S; Varney MA; Depoortere R; Newman-Tancredi A
Neuropharmacology; 2020 May; 167():107997. PubMed ID: 32057799
[TBL] [Abstract][Full Text] [Related]
8. Anti-aggressive effects of the selective high-efficacy 'biased' 5-HT₁A receptor agonists F15599 and F13714 in male WTG rats.
de Boer SF; Newman-Tancredi A
Psychopharmacology (Berl); 2016 Mar; 233(6):937-47. PubMed ID: 26694810
[TBL] [Abstract][Full Text] [Related]
9. Activity of Serotonin 5-HT
Jastrzębska-Więsek M; Partyka A; Rychtyk J; Śniecikowska J; Kołaczkowski M; Wesołowska A; Varney MA; Newman-Tancredi A
ACS Chem Neurosci; 2018 May; 9(5):1040-1050. PubMed ID: 29266914
[TBL] [Abstract][Full Text] [Related]
10. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Dupre KB; Ostock CY; Eskow Jaunarajs KL; Button T; Savage LM; Wolf W; Bishop C
Exp Neurol; 2011 Jun; 229(2):288-99. PubMed ID: 21352823
[TBL] [Abstract][Full Text] [Related]
11. NLX-101, a highly selective 5-HT
Depoortère R; Auclair AL; Newman-Tancredi A
Behav Brain Res; 2021 Mar; 401():113082. PubMed ID: 33358917
[TBL] [Abstract][Full Text] [Related]
12. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline.
Broadbear JH; Depoortere RY; Vacy K; Ralph D; Tunstall BJ; Newman-Tancredi A
Behav Pharmacol; 2021 Dec; 32(8):652-659. PubMed ID: 34751175
[TBL] [Abstract][Full Text] [Related]
14. The selective 5-HT
Głuch-Lutwin M; Sałaciak K; Gawalska A; Jamrozik M; Sniecikowska J; Newman-Tancredi A; Kołaczkowski M; Pytka K
Psychopharmacology (Berl); 2021 Aug; 238(8):2249-2260. PubMed ID: 33973045
[TBL] [Abstract][Full Text] [Related]
15. Serotonin 5-HT
Depoortère R; Bardin L; Varney MA; Newman-Tancredi A
ACS Chem Neurosci; 2019 Jul; 10(7):3101-3107. PubMed ID: 30929419
[TBL] [Abstract][Full Text] [Related]
16. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
17. Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT
Brys I; Halje P; Scheffer-Teixeira R; Varney M; Newman-Tancredi A; Petersson P
Exp Neurol; 2018 Apr; 302():155-168. PubMed ID: 29339052
[TBL] [Abstract][Full Text] [Related]
18. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
[TBL] [Abstract][Full Text] [Related]
19. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
[TBL] [Abstract][Full Text] [Related]
20. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
